CureVac AG has reported positive Phase 1 data from a trial in healthy volunteers of an experimental rabies vaccine based on messenger RNA (mRNA). The prophylactic vaccine, CV7202, encodes the rabies virus glycoprotein RABV-G in a lipid nanoparticle formulation.
